1/6/2023 7:28:37 AM
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split
10/13/2022 10:33:52 AM
Alterity Launches ATH434 Phase 2 Trial In Australia For The Treatment Of Individuals With Multiple System Atrophy
9/20/2022 7:29:54 AM
Alterity Therapeutics: FDA Approves IND Application For ATH434 For Multiple System Atrophy
7/6/2022 11:01:37 AM
Alterity Therapeutics Says Doses First Patient In ATH434 Phase 2 Clinical Trial In Multiple System Atrophy
6/2/2022 8:07:45 AM
Alterity Launches ATH434 Phase 2 Clinical Trial For Treatment Of Patients With Multiple System Atrophy
4/27/2022 7:41:45 AM
Alterity Therapeutics Announces Regulatory Authorization To Proceed With ATH434 Phase 2 Trial In United Kingdom
1/28/2022 7:13:35 AM
Alterity : ATH434 Promising Small Molecule Drug Candidate Has Potential For Treating Multiple System Atrophy
1/6/2022 7:48:32 AM
Alterity Therapeutics Granted New US Patent For Compounds For Neurodegenerative Diseases
12/14/2021 7:27:00 AM
Alterity Therapeutics Announces First Regulatory Authorization To Proceed With ATH434 Phase 2 Clinical Trial
11/5/2021 3:13:30 AM
Alterity Therapeutics : ATH434 Presents Novel Mechanism Of Action For Treatment Of Neurodegenerative Diseases
8/4/2021 8:42:04 AM
Alterity:US Patent To Expand Portfolio Of Compounds For Neurodegenerative Diseases Including Alzheimer's And Parkinson's
7/15/2021 9:55:23 AM
Alterity : ATH434 Reduces ?–synuclein Related Neurodegeneration In Murine Model Of Multiple System Atrophy